Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2019	$ 17,000	$ 232,580,000	$ (235,537,000)	$ (2,878,000)	$ 4,761,000	$ (1,057,000)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Stock-based compensation	$ 0	83,000	0	0	$ 0	83,000
Series A Preferred Stock Dividends	0	0	(62,000)	0	0	(62,000)
Issuance of SYN Biomics Stock	$ 0	0	0	26,000	$ 0	26,000
Conversion of Series B Preferred Stock to Common (in shares)	933,045				(1,073)
Conversion of Series B Preferred Stock to Common	$ 1,000	1,072,000	(404,000)	0	$ (669,000)	0
Net loss	0	0	(2,964,000)		0	(2,964,000)
Non-controlling interest	0	0		(26,000)	0	(26,000)
Balance at Mar. 31, 2020	$ 18,000	233,735,000	(238,967,000)	(2,878,000)	$ 4,092,000	(4,000,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Balance at Dec. 31, 2019	$ 17,000	232,580,000	(235,537,000)	(2,878,000)	$ 4,761,000	(1,057,000)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Net loss						(5,831,000)
Non-controlling interest					$ 100,000	(42,000)
Balance at Jun. 30, 2020	$ 19,000	234,860,000	(242,289,000)	(2,884,000)	$ 3,444,000	(6,850,000)
Balance (in shares) at Jun. 30, 2020	18,643,824				5,525
Balance at Mar. 31, 2020	$ 18,000	233,735,000	(238,967,000)	(2,878,000)	$ 4,092,000	(4,000,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Stock-based compensation	$ 0	86,000			$ 0	86,000
Series A Preferred Stock Dividends	0	0	(63,000)		0	(63,000)
Issuance of SYN Biomics Stock	$ 0	0		10,000	$ 0	10,000
Conversion of Series B Preferred Stock to Common (in shares)	904,349				(1,040)
Conversion of Series B Preferred Stock to Common	$ 1,000	1,039,000	(392,000)		$ (648,000)	0
Net loss	0	0	(2,867,000)		0	(2,867,000)
Non-controlling interest	0	0		(16,000)	100,000	(16,000)
Balance at Jun. 30, 2020	$ 19,000	234,860,000	(242,289,000)	(2,884,000)	$ 3,444,000	(6,850,000)
Balance (in shares) at Jun. 30, 2020	18,643,824				5,525
Balance at Dec. 31, 2020	$ 29,000	240,821,000	(248,094,000)	(2,773,000)	$ 2,477,000	(7,540,000)
Balance (in shares) at Dec. 31, 2020	29,249,925				3,973
Stock-based compensation	$ 0	101,000	0	0	$ 0	101,000
Stock issued under "at-the-market" offering	$ 79,000	65,881,000	0	0	0	65,960,000
Stock issued under "at-the-market" offering (in shares)	78,685,315
Warrants Exercised	$ 12,000	8,030,000	0	0	0	8,042,000
Warrants Exercised (In shares)	11,655,747
Series A Preferred Stock Dividends	$ 0	0	(24,000)		0	(24,000)
Effect of Series A Preferred Stock price adjustment	$ 0	7,402,000	(7,402,000)	0	$ 0	0
Conversion of Series B Preferred Stock to Common (in shares)	3,454,783				(3,973)
Conversion of Series B Preferred Stock to Common	$ 3,000	3,971,000	(1,497,000)	0	$ (2,477,000)	0
Conversion of Series A Preferred Stock to Common	$ 9,000	12,813,000	0	0	0	12,822,000
Conversion of Series A Preferred Stock to Common (in shares)	8,996,768
Net loss	$ 0	0	(2,536,000)		0	(2,536,000)
Non-controlling interest	0	0		(1,000)	0	(1,000)
Balance at Mar. 31, 2021	$ 132,000	339,019,000	(259,553,000)	(2,774,000)	0	76,824,000
Balance (in shares) at Mar. 31, 2021	132,042,538
Balance at Dec. 31, 2020	$ 29,000	240,821,000	(248,094,000)	(2,773,000)	$ 2,477,000	(7,540,000)
Balance (in shares) at Dec. 31, 2020	29,249,925				3,973
Net loss						(5,731,000)
Non-controlling interest					$ 100,000	(1,000)
Balance at Jun. 30, 2021	$ 132,000	339,121,000	(262,748,000)	(2,774,000)	0	73,731,000
Balance (in shares) at Jun. 30, 2021	132,042,538
Balance at Mar. 31, 2021	$ 132,000	339,019,000	(259,553,000)	(2,774,000)	0	76,824,000
Balance (in shares) at Mar. 31, 2021	132,042,538
Stock-based compensation	$ 0	102,000			0	$ 102,000
Warrants Exercised (In shares)						0
Net loss	0	0	(3,195,000)		0	$ (3,195,000)
Non-controlling interest						0
Balance at Jun. 30, 2021	$ 132,000	$ 339,121,000	$ (262,748,000)	$ (2,774,000)	$ 0	$ 73,731,000
Balance (in shares) at Jun. 30, 2021	132,042,538